Detailed Narrative
Q4 & Full Year FY25 Financial Performance
Sanjivani Paranteral Limited reported strong financial performance for Q4 and FY25. Q4 FY25 revenue grew by 41.3% year-on-year to INR 18.2 crores, driven by new products and volume expansion. EBITDA for the quarter was INR 3.1 crores, up 37.9% YoY, with a margin of 16.8%. Profit after tax increased by 74.4% to INR 2.2 crores. For the full fiscal year 2025, revenue reached INR 70.1 crores, marking a 28.8% YoY growth. EBITDA stood at INR 11.6 crores (up 32.1% YoY) with a margin of 16.5%, and PAT was INR 8.1 crores (up 31.4% YoY).
Strategic Expansion and Product Pipeline
The company continues to strengthen its business through focused initiatives, including new product development and geographical expansion. In FY25, 15 new products were added, bringing the total product count to 160. The company plans to launch another 15 to 20 products in FY26. This strategic focus has resulted in robust revenue growth, from INR 17 crores in FY20 to INR 70 crores in FY25.
Joint Venture Progress: IV Products and Nutraceuticals
The SPL Infusion Private Limited (Pune) facility, a 60% equity JV for manufacturing IV products, is now operational with commercial production expected to start shortly. Validation batches are underway, and the facility has a robust order book covering the next 90 days. The Alevia Healthcare S.R.O. (Prague) facility, a 45% equity JV for nutraceuticals, has initiated commercial operations and expects significant expansion in FY26, contributing meaningfully to overall growth. The Prague JV offers white-labeling services in Europe, leveraging a 'Made in Europe' label and cost-effective manufacturing from India.
Operational Highlights and Capacity Utilization
The company's manufacturing facilities underwent multiple regulatory audits, including site approval from a Francophone African nation. Current capacity utilization stands at approximately 65% for the Mumbai plant and 40% for the Dehradun plant. Management expects the Dehradun plant's utilization to ramp up to 50-55%, while Mumbai is targeted to remain at 70-75%. The HAL JV facility is expected to operate at 60-65% capacity utilization in its first year, with order books in place for the first 90 days.
Macro Environment and Sector Outlook
The operating environment for Indian corporates remains broadly positive, with encouraging demand outlooks domestically and in key export markets. The pharmaceutical sector specifically shows intact structural growth trends, benefiting from softening API prices and reduced freight costs. While the evolving US tariff environment introduces some uncertainty, the broader industry outlook remains positive, supported by stable input costs and growing confidence for future investments.
Geographical Market Expansion
Sanjivani Paranteral Limited expanded its geographical footprint into five new regions in FY25. The company is actively entering the French African market, having filed 48 new products in the region, which is expected to drive future growth. In the short term (next 2-3 quarters), the focus remains on existing markets in the Middle East and Latin American zones, where the company is expanding its product portfolio and market presence.